- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00538213
Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥66 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is a year 2 revaccination study. First year revaccination was done in study 104887 (NCT00386698). Primary study was study 104886 (NCT00318149). This study involves 2 age groups (based on primary study):
Subjects enrolled in the ≥ 65 years age group in the primary study. Subjects enrolled in the 18-40 years age group in the primary study.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Gent, Belgique, 9000
- GSK Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects who were previously vaccinated with GlaxoSmithKline Biologicals Fluarix™ or GSK576389A investigational vaccines in the 104887 study (NCT00386698).
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
- A male or female aged between 19 and 42 years or 66 years and older at the time of the vaccination.
- Written informed consent obtained from the subject.
- Free of an acute aggravation of the health status as established by clinical evaluation before entering into the study.
- If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days prior to vaccination, or planned use during the study period.
- Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 21 days after vaccination.
- Planned administration of an influenza vaccine other than the study vaccines during the entire study period.
- Vaccination against influenza since January 2007 with the Northern Hemisphere 2007/2008 influenza vaccine or 2006/2007 influenza vaccine.
- History of confirmed influenza infection since the date of previous vaccination.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. (For corticosteroids, this will mean prednisone, or equivalent, ≥0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- History of hypersensitivity to a previous dose of influenza vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine(s)
- Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests.
- Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Axillary temperature <37.5°C / Oral temperature of <37.5°C).
- Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.
- Any medical conditions in which intramuscular injections are contraindicated.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Adjuvanted influenza vaccine GSK576389A Group
Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
|
Single dose, Intramuscular injection
|
Comparateur actif: Fluarix young Group
Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
|
Dose unique, injection intramusculaire
|
Comparateur actif: Fluarix elderly Group
Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
|
Dose unique, injection intramusculaire
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Durée des événements indésirables généraux sollicités
Délai: Jour 0-6
|
La durée a été définie comme le nombre de jours avec n'importe quel degré de symptômes généraux.
|
Jour 0-6
|
Durée des événements indésirables locaux sollicités
Délai: Jour 0-6
|
La durée a été définie comme le nombre de jours avec n'importe quel degré de symptômes locaux.
|
Jour 0-6
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Délai: Day 0-6
|
Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter i.e. >100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities.
Any was occurrence of any local symptom regardless of their intensity grade.
|
Day 0-6
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Délai: Day 0-6
|
Any temperature was defined as axillary temperature ≥38.0 degree centigrade (°C), grade 3 temperature was axillary temperature ≥39.0°C.
For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as general symptom that prevented normal activity.
Related was general symptom assessed by the investigator as causally related to the study vaccination.
|
Day 0-6
|
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Délai: Day 0-20
|
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.
Grade 3 was event that prevented normal activities and related was defined as unsolicited AE assessed by the investigator to be causally related to the study vaccination.
|
Day 0-20
|
Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs)
Délai: Day 0-20
|
MSCs were defined as AEs with a medically-attended visit i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination.
At least one MSC was defined as at least one MSC experienced.
Grade 3 was MSC that prevented normal activities and Related was defined as MSC assessed by the investigator to be causally related to the study vaccination.
|
Day 0-20
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)
Délai: Day 0-20
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.
|
Day 0-20
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Haemagglutination Inhibition (HI) Antibody Titers
Délai: At Days 0 and 21
|
Antibody titers were expressed as Geometric mean titers (GMTs).
The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
|
At Days 0 and 21
|
The Number of Subjects Seropositive to HI Antibodies
Délai: At Days 0 and 21
|
Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e. ≥ 1:10.
The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
|
At Days 0 and 21
|
The Number of Subjects Seroconverted to HI Antibodies
Délai: At Day 21
|
Seroconversion was defined as either a pre-vaccination titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a 4-fold increase in post-vaccination titer.
The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
|
At Day 21
|
HI Antibody Seroconversion Factors (SCF)
Délai: At Day 21
|
SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
|
At Day 21
|
The Number of Subjects Seroprotected to HI Antibodies
Délai: At Days 0 and 21
|
Seroprotection was defined as serum HI titer ≥1:40 that usually is accepted as indicating protection.
The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
|
At Days 0 and 21
|
The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker
Délai: At Days 0 and 21
|
The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were Cluster of Differentiation 4-All doubles i.e.
CD4-All doubles, CD40 Ligand (CD40L), interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).
|
At Days 0 and 21
|
The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker
Délai: At Days 0 and 21
|
The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were CD8-All doubles, CD40L, IFN-γ, IL-2 and TNF-α.
|
At Days 0 and 21
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 110263
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Données/documents d'étude
-
Spécification du jeu de données
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Rapport d'étude clinique
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulaire de rapport de cas annoté
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan d'analyse statistique
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Ensemble de données de participant individuel
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulaire de consentement éclairé
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocole d'étude
Identifiant des informations: 110263Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Grippe
-
Mitsubishi Tanabe Pharma CorporationComplété
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDComplétéGroupe A, C Méningite polysaccharidique | Haemophilus Influenza de type bChine
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.Complété
-
University Hospital, LilleCSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; O... et autres collaborateursRésiliéInfections pneumococciques | Pneumonie bactérienne | Méningite bactérienne | Otite moyenne | Infection chronique des sinus | Infection streptococcique | Déficit en anticorps | Carence en complément | Infections à Neisseria | Haemophilus InfluenzaFrance
-
QIAGEN Gaithersburg, IncComplétéInfections par le virus respiratoire syncytial | Grippe A | Rhinovirus | Grippe B | Panneau avancé QIAGEN ResPlex II | Infection due au virus parainfluenza humain 1 | Parainfluenza de type 2 | Parainfluenza de type 3 | Parainfluenza de type 4 | Métapneumovirus humain A/B | Virus/échovirus Coxsackie | Adénovirus... et d'autres conditionsÉtats-Unis
Essais cliniques sur FluarixMC
-
BaroNova, Inc.Complété
-
Asklepios Kliniken Hamburg GmbHUniversity of KielComplétéGestion des voies respiratoires | Voies respiratoires du masque laryngé | Intubation par fibre optique
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalInconnueLésions cérébrales chroniques | Cerebellar Cognitive Affective Syndrome | Mutisme cérébelleux
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalInconnueÉpilepsie du lobe temporal
-
Medtronic CardiovascularActif, ne recrute pasAnévrisme aortiqueAllemagne, Nouvelle-Zélande, États-Unis, Pays-Bas, Suisse, Royaume-Uni, Espagne, Australie, Italie, Suède, France, L'Autriche, Slovaquie
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecrutementHydrocéphalie | Hydrocéphalie, CommuniquerArgentine
-
Fisher and Paykel HealthcareSleep Health CentersRésilié
-
Aubrey Inc.InconnueTraitement des brûlures du site donneurÉtats-Unis
-
novoGIComplétéLymphome | Tumeurs colorectales | Endométriose | Maladie de Crohn | Colite ulcéreuse | Polypose intestinale | Iléostomie - Stomie | Volvulus intestinal | Colostomie | Diverticule, côlon | Prolapsus rectalÉtats-Unis
-
Boston Scientific CorporationComplétéAccident ischémique transitoire | AVC thromboembolique | Prévention des AVCÉtats-Unis, Argentine, Allemagne